These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35909272)

  • 21. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH.
    Tortellini E; Zingaropoli MA; Mancarella G; Marocco R; Carraro A; Jamhour M; Barbato C; Guardiani M; Dominelli F; Pasculli P; Napoli A; Gaeta A; Mengoni F; Zuccalà P; Belvisi V; Kertusha B; Parente A; Del Borgo C; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M; Latina Covid-Group
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City.
    Soto-Nava M; Dávila-Conn V; Venancio-Rocha JP; García-Esparza P; Tapia-Trejo D; Hernández-Juan R; Zarza-Sánchez E; Murakami-Ogasawara A; Ávila-Ríos S
    Virol J; 2023 Dec; 20(1):300. PubMed ID: 38102622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    Cai S; Liao G; Yu T; Gao Q; Zou L; Zhang H; Xu X; Chen J; Lu A; Wu Y; Li B; Peng J
    J Med Virol; 2022 Sep; 94(9):4224-4233. PubMed ID: 35585023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    Tuan JJ; Zapata H; Critch-Gilfillan T; Ryall L; Turcotte B; Mutic S; Andrews L; Roh ME; Friedland G; Barakat L; Ogbuagu O
    HIV Med; 2022 Feb; 23(2):178-185. PubMed ID: 34632695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
    Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
    Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
    Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Immunol; 2022; 13():868361. PubMed ID: 35833113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals.
    Yang X; Wang X; Zhang X; Ding H; Wang H; Huang T; Zhang G; Duan J; Xia W; Su B; Jin C; Wu H; Zhang T
    Chin Med J (Engl); 2023 Dec; 136(24):2948-2959. PubMed ID: 38018259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
    Mondi A; Cimini E; Colavita F; Cicalini S; Pinnetti C; Matusali G; Casetti R; Maeurer M; Vergori A; Mazzotta V; Gagliardini R; De Zottis F; Schininà V; Girardi E; Puro V; Ippolito G; Vaia F; Capobianchi MR; Castilletti C; Agrati C; Antinori A
    J Med Virol; 2021 Mar; 93(3):1796-1804. PubMed ID: 32975842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
    Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
    Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
    Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
    BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Uwamino Y; Yokoyama T; Shimura T; Nishimura T; Sato Y; Wakui M; Kosaki K; Hasegawa N; Murata M
    Vaccine; 2022 Mar; 40(13):1928-1931. PubMed ID: 35183387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.
    Marot S; Malet I; Leducq V; Abdi B; Teyssou E; Soulie C; Wirden M; Rodriguez C; Fourati S; Pawlotsky JM; Boutolleau D; Burrel S; Calvez V; Marcelin AG; Jary A
    Clin Infect Dis; 2022 Mar; 74(4):707-710. PubMed ID: 34050731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.